NYSE · STVN
Healthcare · Medical - Instruments & Supplies
$19.31
Up+$0.05 (+0.26%)
Updated Oct 15, 2026, 4:19 AM
SID Score
4.0/10
Composite research score
Smart Money
56/100
Neutral
Price performance · STVN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 14, 2026
STVN closed at $19.31 after 21 trading sessions, down 14.29% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 14, 2026 | $19.11 | $19.54 | $19.01 | $19.31 | 360.57K |
| Oct 13, 2026 | $19.20 | $19.478 | $18.82 | $19.26 | 398.48K |
| Oct 12, 2026 | $19.755 | $19.755 | $19.10 | $19.24 | 301.08K |
| Oct 9, 2026 | $19.22 | $19.82 | $19.22 | $19.40 | 267.1K |
| Oct 8, 2026 | $19.44 | $19.55 | $19.00 | $19.21 | 233.1K |
| Oct 7, 2026 | $19.61 | $19.86 | $19.18 | $19.44 | 285.69K |
| Oct 6, 2026 | $20.21 | $20.9099 | $19.64 | $19.86 | 236.05K |
| Oct 5, 2026 | $20.20 | $20.415 | $19.88 | $20.05 | 652.58K |
| Oct 2, 2026 | $20.07 | $20.51 | $19.84 | $20.20 | 189.92K |
| Oct 1, 2026 | $20.70 | $20.7987 | $19.51 | $19.98 | 202.85K |
| Sep 30, 2026 | $21.415 | $21.52 | $20.94 | $20.98 | 192.81K |
| Sep 29, 2026 | $21.25 | $21.395 | $20.89 | $21.20 | 205.9K |
| Sep 28, 2026 | $21.03 | $21.565 | $20.81 | $21.41 | 306.63K |
| Sep 25, 2026 | $21.26 | $21.39 | $20.74 | $21.13 | 286.24K |
| Sep 24, 2026 | $21.50 | $21.72 | $20.91 | $21.38 | 191.74K |
| Sep 23, 2026 | $21.51 | $21.79 | $20.905 | $21.69 | 205.78K |
| Sep 22, 2026 | $21.42 | $21.91 | $21.0663 | $21.70 | 217.44K |
| Sep 21, 2026 | $21.91 | $22.17 | $21.185 | $21.51 | 475.48K |
| Sep 18, 2026 | $22.60 | $23.254 | $21.61 | $21.70 | 265.55K |
| Sep 17, 2026 | $22.66 | $23.18 | $22.53 | $22.67 | 507.12K |
| Sep 16, 2026 | $21.51 | $22.53 | $21.43 | $22.53 | 603.5K |
The latest Smart Investors Daily articles mentioning STVN.
Company
Market Activity
Research & News
STVN research
Company profile and research snapshot.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Neutral | — |
| Jun 16, 2026 | TD Cowen | Buy | — |
| Mar 6, 2026 | Morgan Stanley | Equal-Weight | — |
| Mar 5, 2026 | Citigroup | Buy | — |
| Mar 5, 2026 | Keybanc | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 1, 2026
Ensera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, bringing together leading device platform and fill-finish specialists to address the complexity of commercializing drug-device combination products.
Yahoo · Oct 1, 2026
United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SeekingAlpha · Sep 15, 2026
Stevanato Group S.p.A. (STVN) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 1:50 PM EDTCompany ParticipantsMarco Dal Lago -...
SeekingAlpha · Sep 11, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning STVN.
